Critical Analysis: Embecta (NASDAQ:EMBC) vs. Sanara MedTech (NASDAQ:SMTI)

Sanara MedTech (NASDAQ:SMTI) and Embecta (NASDAQ:EMBC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, earnings, institutional ownership, risk, analyst recommendations and valuation.

Profitability

This table compares Sanara MedTech and Embecta’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	29.72%	2.84%
Embecta	8.59%	-19.25%	10.82%

Volatility and Risk

Sanara MedTech has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Embecta has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Earnings & Valuation

This table compares Sanara MedTech and Embecta”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$109.81 million	2.94	-$37.56 million	($3.59)	-9.78
Embecta	$1.02 billion	0.31	$95.40 million	$1.48	3.80

Embecta has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by company insiders. Comparatively, 1.3% of Embecta shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Sanara MedTech and Embecta, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1	4	0	0	1.80
Embecta	2	3	0	0	1.60

Sanara MedTech presently has a consensus price target of $35.00, suggesting a potential downside of 0.28%. Embecta has a consensus price target of $11.00, suggesting a potential upside of 95.73%. Given Embecta’s higher probable upside, analysts clearly believe Embecta is more favorable than Sanara MedTech.

Summary

Embecta beats Sanara MedTech on 8 of the 13 factors compared between the two stocks.

About Sanara MedTech

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.